Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HL03/WBP263 versus Rituxan with CHOP in previously untreated diffuse large B-cell lymphoma
CTR20190424Phase 3Completed
- Sponsor
- Hualan Ankang Biotechnology
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HL03/WBP263, sponsored by Hualan Ankang Biotechnology. Started Aug 2019; status: completed.
02
Drugs
HL03/WBP263
Beyond the preview
Go deeper on CTR20190424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190424.